Angiotensin-converting enzyme inhibitors: are there credible mechanisms for beneficial effects in diabetic neuropathy?
Malik
Rayaz A
RA
Department of Medicine, Manchester Royal Infirmary, Manchester M13 9WL, United Kingdom.
Tomlinson
David R
DR
D000804:Angiotensin II / Q000502:physiology; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use*; D000818:Animals; D001808:Blood Vessels / Q000187:drug effects / Q000473:pathology; D006801:Humans; D010525:Peripheral Nerves / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D012084:Renin-Angiotensin System / Q000502:physiology; D014650:Vasa Nervorum / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology
D000806:Angiotensin-Converting Enzyme Inhibitors; D000804:Angiotensin II